An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Paitients With EGFR Mutation

Trial Profile

An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Paitients With EGFR Mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Icotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Zhejiang Betta Pharma
  • Most Recent Events

    • 05 Sep 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified sep 2015).
    • 07 Jun 2016 Results analyzing efficacy and safety of icotinib presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top